Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Inclusion Criteria: Stage I-III Criteria- * Patients aged 18 years or over who had had a macroscopically curative resection for gastric adenocarcinoma. * Absence of metastatic disease evident from: * physical examination * the most recent chest X-ray * abdominal CT or ultrasound scan * Life expectancy of at least 3 months * WHO performance status of 0 to 1 * Written informed consent given Stage IV Criteria- * Patients aged 18 years or over with Stage IV gastric cancer: carcinoma with the primary tumour invading the adjacent structures and/or involvement of more than 15 regional lymph nodes and/or distant metastases * Life expectancy of at least 3 months * WHO performance status of 0 to 2 * Written informed consent given Exclusion Criteria: * History of other malignant disease except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix Recurrent gastric cancer following previous surgery Presence of metastatic disease: peritoneal deposits or involved lymph nodes outside the limit of resection * Previous use, concomitant use or anticipated use in the period of the study, of any anti-cancer therapies * Concomitant use of immunosuppressants, including systemic (ie oral or injected) corticosteroids * Females who were pregnant, planning to become pregnant or lactating * Patients who were taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during this study * Previous G17DT treatment * Haematological indicators: * Haemoglobin \<10.0g/dl * White blood cell count \<4.0 x 109/l * Platelets \<100 x 109/l